Daily Ards Research Analysis
A single new ARDS-related study links a serum microRNA (miR-6515-5p) to fibrotic complications and outcomes. It suggests diagnostic and prognostic utility, correlating with lung function and severity indices, but requires external validation before clinical adoption.
Summary
A single new ARDS-related study links a serum microRNA (miR-6515-5p) to fibrotic complications and outcomes. It suggests diagnostic and prognostic utility, correlating with lung function and severity indices, but requires external validation before clinical adoption.
Research Themes
- Biomarkers for ARDS
- Pulmonary fibrosis complications
- MicroRNA-based diagnostics and prognostication
Selected Articles
1. Clinical significance of miR-6515-5p in predicting diagnosis and prognosis for acute respiratory distress syndrome suffering from pulmonary fibrosis.
Serum miR-6515-5p levels were reduced in ARDS, especially in cases with pulmonary fibrosis, and correlated with lower FVC/DLCO and higher severity scores. ROC, logistic regression, and survival analyses suggest miR-6515-5p has diagnostic and prognostic value for ARDS with fibrotic complications.
Impact: It proposes a serum microRNA biomarker that integrates disease severity, fibrotic phenotype, and outcomes in ARDS—an area with unmet need for risk stratification.
Clinical Implications: If validated, miR-6515-5p could support early identification of ARDS patients at risk of pulmonary fibrosis and poor outcomes, guiding monitoring intensity and enrollment into anti-fibrotic or precision trials.
Key Findings
- Serum miR-6515-5p is downregulated in ARDS, with the greatest reduction in patients with pulmonary fibrosis.
- Lower miR-6515-5p associates with reduced FVC and DLCO and higher Murray and APACHE II scores.
- miR-6515-5p shows diagnostic discrimination for ARDS vs healthy controls and for ARDS with PLF vs without (ROC analysis).
- Lower miR-6515-5p predicts worse outcomes in ARDS with PLF by Kaplan–Meier and multivariable Cox analyses.
Methodological Strengths
- Use of complementary statistical approaches (ROC, logistic regression, Kaplan–Meier, multivariable Cox).
- Clinical correlation with functional indices (FVC, DLCO) and severity scores (Murray, APACHE II).
Limitations
- Sample size, multicenter status, and external validation cohort are not reported in the abstract.
- No predefined cut-offs or mechanistic experiments to support biological causality of miR-6515-5p.
Future Directions: Prospective, multicenter validation with predefined cut-offs, external replication cohorts, assay standardization, and mechanistic studies to define miR-6515-5p’s role in fibrotic remodeling.
BACKGROUND: The high mortality rate of ARDS is closely related to pulmonary fibrosis (PLF), and the degree of pulmonary fibrosis affects the prognosis of ARDS. Numerous studies indicated the abnormal expression of miRNAs in the pathogenesis of various lung diseases, such as ARDS and PLF. This study aimed to explore the expression of serum miR-6515-5p and its clinical performance in ARDS complicated with PLF. METHODS: RT-qPCR analysis was employed to measure miR-6515-5p levels within the serum specimens from ARDS patients who either had PLF or did not. Receiver Operating Characteristics (ROC) curve was conducted to evaluate the diagnostic value of miR-6515-5p. To analyze the risk factors linked with the development of PLF in ARDS patients, logistic regression analysis was conducted. Kaplan-Meier curve was conducted to assess the prognostic value of miR-6515-5p in predicting the outcome of ARDS patients with PLF. Multivariate COX regression analysis was performed to identify the PLF-related risk factors associated with outcomes. RESULTS: Serum miR-6515-5p was downregulated in ARDS patients, especially in patients suffering from PLF. miR-6515-5p expression can distinguish ARDS patients from healthy individuals and related to the occurrence of PLF. Most patients with low miR-6515-5p expression had low FVC and DLCO, as well as high Murray score and APACHE II score. Moreover, miR-6515-5p expression has a certain high value in differentiating ARDS patients with PLF from those without PLF. In addition, miR-6515-5p may be a prognostic marker in ARDS patients suffering from PLF. CONCLUSIONS: These data identified the abnormal expression of miR-6515-5p in ARDS and PLF, and implied a potential clinical early diagnostic and prognostic marker in ARDS suffering from PLF.
2. Clinical significance of miR-6515-5p in predicting diagnosis and prognosis for acute respiratory distress syndrome suffering from pulmonary fibrosis.
Serum miR-6515-5p levels were reduced in ARDS, especially in cases with pulmonary fibrosis, and correlated with lower FVC/DLCO and higher severity scores. ROC, logistic regression, and survival analyses suggest miR-6515-5p has diagnostic and prognostic value for ARDS with fibrotic complications.
Impact: It proposes a serum microRNA biomarker that integrates disease severity, fibrotic phenotype, and outcomes in ARDS—an area with unmet need for risk stratification.
Clinical Implications: If validated, miR-6515-5p could support early identification of ARDS patients at risk of pulmonary fibrosis and poor outcomes, guiding monitoring intensity and enrollment into anti-fibrotic or precision trials.
Key Findings
- Serum miR-6515-5p is downregulated in ARDS, with the greatest reduction in patients with pulmonary fibrosis.
- Lower miR-6515-5p associates with reduced FVC and DLCO and higher Murray and APACHE II scores.
- miR-6515-5p shows diagnostic discrimination for ARDS vs healthy controls and for ARDS with PLF vs without (ROC analysis).
- Lower miR-6515-5p predicts worse outcomes in ARDS with PLF by Kaplan–Meier and multivariable Cox analyses.
Methodological Strengths
- Use of complementary statistical approaches (ROC, logistic regression, Kaplan–Meier, multivariable Cox).
- Clinical correlation with functional indices (FVC, DLCO) and severity scores (Murray, APACHE II).
Limitations
- Sample size, multicenter status, and external validation cohort are not reported in the abstract.
- No predefined cut-offs or mechanistic experiments to support biological causality of miR-6515-5p.
Future Directions: Prospective, multicenter validation with predefined cut-offs, external replication cohorts, assay standardization, and mechanistic studies to define miR-6515-5p’s role in fibrotic remodeling.
BACKGROUND: The high mortality rate of ARDS is closely related to pulmonary fibrosis (PLF), and the degree of pulmonary fibrosis affects the prognosis of ARDS. Numerous studies indicated the abnormal expression of miRNAs in the pathogenesis of various lung diseases, such as ARDS and PLF. This study aimed to explore the expression of serum miR-6515-5p and its clinical performance in ARDS complicated with PLF. METHODS: RT-qPCR analysis was employed to measure miR-6515-5p levels within the serum specimens from ARDS patients who either had PLF or did not. Receiver Operating Characteristics (ROC) curve was conducted to evaluate the diagnostic value of miR-6515-5p. To analyze the risk factors linked with the development of PLF in ARDS patients, logistic regression analysis was conducted. Kaplan-Meier curve was conducted to assess the prognostic value of miR-6515-5p in predicting the outcome of ARDS patients with PLF. Multivariate COX regression analysis was performed to identify the PLF-related risk factors associated with outcomes. RESULTS: Serum miR-6515-5p was downregulated in ARDS patients, especially in patients suffering from PLF. miR-6515-5p expression can distinguish ARDS patients from healthy individuals and related to the occurrence of PLF. Most patients with low miR-6515-5p expression had low FVC and DLCO, as well as high Murray score and APACHE II score. Moreover, miR-6515-5p expression has a certain high value in differentiating ARDS patients with PLF from those without PLF. In addition, miR-6515-5p may be a prognostic marker in ARDS patients suffering from PLF. CONCLUSIONS: These data identified the abnormal expression of miR-6515-5p in ARDS and PLF, and implied a potential clinical early diagnostic and prognostic marker in ARDS suffering from PLF.
3. Clinical significance of miR-6515-5p in predicting diagnosis and prognosis for acute respiratory distress syndrome suffering from pulmonary fibrosis.
Serum miR-6515-5p levels were reduced in ARDS, especially in cases with pulmonary fibrosis, and correlated with lower FVC/DLCO and higher severity scores. ROC, logistic regression, and survival analyses suggest miR-6515-5p has diagnostic and prognostic value for ARDS with fibrotic complications.
Impact: It proposes a serum microRNA biomarker that integrates disease severity, fibrotic phenotype, and outcomes in ARDS—an area with unmet need for risk stratification.
Clinical Implications: If validated, miR-6515-5p could support early identification of ARDS patients at risk of pulmonary fibrosis and poor outcomes, guiding monitoring intensity and enrollment into anti-fibrotic or precision trials.
Key Findings
- Serum miR-6515-5p is downregulated in ARDS, with the greatest reduction in patients with pulmonary fibrosis.
- Lower miR-6515-5p associates with reduced FVC and DLCO and higher Murray and APACHE II scores.
- miR-6515-5p shows diagnostic discrimination for ARDS vs healthy controls and for ARDS with PLF vs without (ROC analysis).
- Lower miR-6515-5p predicts worse outcomes in ARDS with PLF by Kaplan–Meier and multivariable Cox analyses.
Methodological Strengths
- Use of complementary statistical approaches (ROC, logistic regression, Kaplan–Meier, multivariable Cox).
- Clinical correlation with functional indices (FVC, DLCO) and severity scores (Murray, APACHE II).
Limitations
- Sample size, multicenter status, and external validation cohort are not reported in the abstract.
- No predefined cut-offs or mechanistic experiments to support biological causality of miR-6515-5p.
Future Directions: Prospective, multicenter validation with predefined cut-offs, external replication cohorts, assay standardization, and mechanistic studies to define miR-6515-5p’s role in fibrotic remodeling.
BACKGROUND: The high mortality rate of ARDS is closely related to pulmonary fibrosis (PLF), and the degree of pulmonary fibrosis affects the prognosis of ARDS. Numerous studies indicated the abnormal expression of miRNAs in the pathogenesis of various lung diseases, such as ARDS and PLF. This study aimed to explore the expression of serum miR-6515-5p and its clinical performance in ARDS complicated with PLF. METHODS: RT-qPCR analysis was employed to measure miR-6515-5p levels within the serum specimens from ARDS patients who either had PLF or did not. Receiver Operating Characteristics (ROC) curve was conducted to evaluate the diagnostic value of miR-6515-5p. To analyze the risk factors linked with the development of PLF in ARDS patients, logistic regression analysis was conducted. Kaplan-Meier curve was conducted to assess the prognostic value of miR-6515-5p in predicting the outcome of ARDS patients with PLF. Multivariate COX regression analysis was performed to identify the PLF-related risk factors associated with outcomes. RESULTS: Serum miR-6515-5p was downregulated in ARDS patients, especially in patients suffering from PLF. miR-6515-5p expression can distinguish ARDS patients from healthy individuals and related to the occurrence of PLF. Most patients with low miR-6515-5p expression had low FVC and DLCO, as well as high Murray score and APACHE II score. Moreover, miR-6515-5p expression has a certain high value in differentiating ARDS patients with PLF from those without PLF. In addition, miR-6515-5p may be a prognostic marker in ARDS patients suffering from PLF. CONCLUSIONS: These data identified the abnormal expression of miR-6515-5p in ARDS and PLF, and implied a potential clinical early diagnostic and prognostic marker in ARDS suffering from PLF.